Share Email Print
cover

Proceedings Paper

In vitro therapeutic effect of PDT combined with VEGF-A gene therapy
Author(s): Rumwald Leo G. Lecaros; Leaf Huang; Yih-Chih Hsu
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Vascular endothelial growth factor A (VEGF-A), commonly known as VEGF, is one of the primary factors that affect tumor angiogenesis. It was found to be expressed in cancer cell lines including oral squamous cell carcinoma. Photodynamic therapy (PDT) is a novel therapeutic modality to treat cancer by using a photosensitizer which is activated by a light source to produce reactive oxygen species and mediates oxygen-independent hypoxic conditions to tumor. Another emerging treatment to cure cancer is the use of interference RNA (e.g. siRNA) to silence a specific mRNA sequence. VEGF-A was found to be expressed in oral squamous cell carcinoma and overexpressed after 24 hour post-PDT by Western blot analysis. Cell viability was found to decrease at 25 nM of transfected VEGF-A siRNA. In vitro combined therapy of PDT and VEGF-A siRNA showed better response as compared with PDT and gene therapy alone. The results suggest that PDT combined with targeted gene therapy has a potential mean to achieve better therapeutic outcome.

Paper Details

Date Published: 27 February 2014
PDF: 6 pages
Proc. SPIE 8944, Biophotonics and Immune Responses IX, 894405 (27 February 2014); doi: 10.1117/12.2042979
Show Author Affiliations
Rumwald Leo G. Lecaros, Chung Yuan Christian Univ. (Taiwan)
Leaf Huang, Chung Yuan Christian Univ. (United States)
UNC Eshelman School of Pharmacy (Taiwan)
Yih-Chih Hsu, Chung Yuan Christian Univ. (Taiwan)


Published in SPIE Proceedings Vol. 8944:
Biophotonics and Immune Responses IX
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top